Longitudinal Analyses of Blood Lipids and Future Risk of Dementia in CPRD (Lipids and dementia)

Study identification

• EU PAS number:
  EUPAS23959
• Study ID:
  40836
• Official title and acronym:
  Longitudinal Analyses of Blood Lipids and Future Risk of Dementia in CPRD (Lipids and dementia)
• DARWIN EU® study:
  No
• Study countries:
  Spain

  United Kingdom
• Study description:
  Establishing modifiable risk factors of dementia risk is a global priority. The relationship of lipids to the risk of developing dementia is unclear. Previous research based on small studies suggests that people who have high cholesterol in midlife may have an increased risk of developing dementia some 20 years later. The proposed study will use information from a large number of people in the UK to investigate the relationship between lipids (total cholesterol, LDL and HDL) and the future risk of developing dementia. People aged 40 years or older with a lipid reading between 1992 and 2009 will be selected from the CPRD primary care database. Their recorded development of dementia will be investigated, whilst accounting for differences in characteristics (e.g. age, gender, etc.). This study will provide information from a very large number of people with a sizeable amount of follow-up data which will be representative of the UK population. The findings will therefore provide important information to help clarify the relationship between lipids and dementia. The findings will help to inform preventative strategies for dementia.
• Study status:
  Planned

Research institutions and networks

Institutions

OXON Epidemiology

Spain

United Kingdom

Electronic Health Records (EHR) Research Group, London School of Hygiene & Tropical Medicine (LSHTM)

United Kingdom

OXON Epidemiology

Spain

United Kingdom

Study timelines

Date when funding contract was signed

Planned:01/06/2016

Actual:01/06/2016

Study start date

Planned:15/09/2016

Date of final study report

Planned:31/05/2018

Sources of funding

Non-for-profit organisation (e.g. charity)

More details on funding

Alzheimer´s Society

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable